Biogen Inc. ((BIIB)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biogen Inc. is conducting a Phase 3 long-term extension study titled A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus. The study aims to assess the long-term safety and efficacy of litifilimab in adults with active systemic lupus erythematosus (SLE) who have completed previous treatment periods in parent studies. The primary focus is on understanding adverse events and the drug’s impact on SLE symptoms.
The intervention being tested is litifilimab, administered as subcutaneous injections every four weeks. The study also includes a placebo group for comparison. Litifilimab is designed to manage symptoms and reduce disease activity in SLE patients.
This study is interventional with a randomized, parallel assignment model. It employs quadruple masking to ensure unbiased results, with the primary purpose being treatment. Participants will continue their standard care medications alongside the study drug.
The study began on April 25, 2022, with an estimated primary completion date in 2025. The last update was submitted on October 23, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The update on this study could influence Biogen’s stock performance positively, as successful results might enhance investor confidence and market position. The competitive landscape in the SLE treatment market may also be affected, with potential implications for other companies developing similar therapies.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.